You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
New IPO: Beauty and Healthcare Retailer Lung Fung Group Debuts in Hong Kong

Lung Fung Group Holdings Limited (02290.HK) has launched its Hong Kong IPO. The offering period runs from May 28 to June 2, 2026. The company plans to globally offer 125,000,000 shares, subject to a 15% over-allotment option. The offer price ranges from HK$5.18 to HK$6.38 per share, with a board lot size of 500 shares and an entry fee of approximately HK$3,222.17. The shares are expected to be listed on the Main Board of the Stock Exchange of Hong Kong on June 5, 2026. DBS Asia Capital Limited is acting as the sole sponsor.

Lung Fung Group: Hong Kong’s Third-Largest Beauty, Healthcare and Pharmaceutical Retailer

Offering structure: Hong Kong public offering approximately 10% (12,500,000 shares), international placing approximately 90% (112,500,000 shares).

Offer price: HK$5.18–HK$6.38 per share; board lot size of 500 shares; entry fee of approximately HK$3,222.17.

Offering period: May 28, 2026 – June 2, 2026 (expected pricing date: June 3, 2026).

Listing date: June 5, 2026.

IPO sponsor: DBS Asia Capital Limited.

 

Company Overview

Lung Fung Group Holdings Limited is a Hong Kong-based chain retailer of beauty products, healthcare products and pharmaceuticals operating under the “Lung Fung” brand. According to Frost & Sullivan, in fiscal year 2025, the group ranked third among beauty products, healthcare products and pharmaceutical retailers in Hong Kong by retail sales, with a market share of approximately 5.8%. By retail sales, it was also the largest pharmaceutical retailer in Hong Kong, with a market share of approximately 5.2%. As of the latest practicable date, the group operated 31 retail stores in Hong Kong and also sold products through its official online store and online platforms including Tmall, WeChat Mini Program and JD.com.

 

Financial Information

According to the prospectus, Lung Fung Group recorded revenue of approximately HK$1.094 billion, HK$2.021 billion and HK$2.460 billion for the fiscal years 2023–2025 (years ended March 31), respectively. During the same periods, the group recorded loss/net profit of approximately negative HK$27 million, HK$145 million and HK$170 million, respectively. For the first eight months of fiscal year 2026, the group recorded revenue of approximately HK$2.035 billion and net profit of approximately HK$148 million. Based on the midpoint offer price of HK$5.78 per share, assuming the over-allotment option is not exercised, the company expects net proceeds of approximately HK$672 million. The proceeds are intended to be used for expanding, strengthening and optimizing its offline and online sales network (approximately 36.6%), pursuing strategic investments and acquisition opportunities (approximately 15.0%), repayment of outstanding loans (approximately 20.0%), upgrading IT systems (approximately 11.4%), brand management and marketing (approximately 3.5%), enhancing supply chain capabilities (approximately 3.5%), and general working capital purposes (approximately 10.0%).

 

uSMART launches “HK IPO Fee-Waiver Offer” – subscribe to new shares at zero cost

Margin subscription: 0 % interest, leverage up to 10×

Cash subscription: HK$0 handling fee

Grey-market trading supported

* 0 % interest applies to margin subscription amounts of HK$20 million or below.

^ All handling fees are waived for cash subscriptions.

This promotion is effective from 5 December 2025 until further notice. Certain high-profile IPOs may be excluded. The actual interest rates and fees charged are those shown in the uSMART App subscription interface; statutory government and exchange levies will still apply. The company reserves the right to amend, suspend or terminate the above offer or its terms and conditions at any time without prior notice, and its interpretation shall be final.

How to Subscribe for Lung Fung Group via uSMART HK

The uSMART HK App features an IPO Centre with exclusive perks, allowing clients to subscribe instantly to public offerings. After logging into the app, tap "Trade" at the bottom-right, go to "IPO Subscription," select Lung Fung Group, tap "Public Offer," enter your subscription quantity, and submit your order.

(Image source: uSMART HK App)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account